2020
Inhibition of MUC1 exerts cell-cycle arrest and telomerase suppression in glioblastoma cells
Kim S, Seo Y, Chowdhury T, Yu H, Lee C, Kim K, Kang H, Kim H, Park S, Kim K, Park C. Inhibition of MUC1 exerts cell-cycle arrest and telomerase suppression in glioblastoma cells. Scientific Reports 2020, 10: 18238. PMID: 33106534, PMCID: PMC7589558, DOI: 10.1038/s41598-020-75457-z.Peer-Reviewed Original ResearchConceptsRole of MUC1Epithelial-mesenchymal transitionMucin 1Cell cycle arrestMUC1 knockdownNormal brain tissueExpression levelsGrowth factor betaTERT expression levelsGBM cell linesOverall survivalTherapeutic targetOncological processHuman gliomasBrain tissueFactor betaMesenchymal transitionPhosphorylation of RB1Diverse cancersGlioblastomaTelomere maintenance mechanismAnticancer mechanismCell proliferationCycle arrestGlioblastoma cells
2018
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
Hung A, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik A, Kim E, Wu A, Xia Y, Garzon-Muvdi T, Jackson C, Ye X, Tyler B, Selby M, Korman A, Barnhart B, Park S, Youn J, Chowdhury T, Park C, Brem H, Pardoll D, Lim M. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. OncoImmunology 2018, 7: e1466769. PMID: 30221069, PMCID: PMC6136875, DOI: 10.1080/2162402x.2018.1466769.Peer-Reviewed Original ResearchTumor-infiltrating dendritic cellsCervical lymph nodesTIGIT expressionT cellsTherapeutic targetEffector T cell functionDual checkpoint blockadePatient GBM samplesUnderlying immune mechanismsRegulatory T cellsTumor-infiltrating lymphocytesPoor survival outcomesNovel checkpoint inhibitorsT cell functionManagement of glioblastomaEffective treatment strategiesImmune therapeutic targetsLow-grade gliomasHuman GBM cellsMurine glioblastoma modelValuable therapeutic targetSuppressive TregsTIGIT pathwayCheckpoint inhibitorsInhibitory checkpoints